The corticostriatal pathway in Huntington's disease
Authors:
- V AndreVAV Andre
- M LevineMLM Levine
- 1 April 2007
- journal article
- review article
- Published by Elsevier in Progress in Neurobiology
- Vol. 81 (5-6) , 253-271
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansionNature Genetics, 1997
- Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in BrainScience, 1997
- Activation of adenosine A 1 receptors initiates short-term synaptic depression in rat striatumNeuroscience Letters, 1995
- 3‐Nitropropionic Acid Toxicity in the StriatumJournal of Neurochemistry, 1994
- Endogenous GABA mediates presynaptic inhibition of spontaneous and evoked excitatory synaptic potentials in the rat neostriatumNeuroscience Letters, 1990
- Degeneration of pyramidal projection neurons in Huntington's disease cortexAnnals of Neurology, 1990
- A controlled clinical trial of baclofen as protective therapy in early huntington's diseaseAnnals of Neurology, 1989
- A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia.Journal of Neurology, Neurosurgery & Psychiatry, 1984
- Effects of cortical ablation on the neurotoxicity and receptor binding of kainic acid in striatumJournal of Neuroscience Research, 1979
- Huntington'S disease: Treatment with muscimol, A GABA‐mimetic drugAnnals of Neurology, 1978